Newsfilter article unlocker

We always have to be careful when discussing pooled data because there are minor differences in the protocol between the trials. But when you combine this interim phase three data with the phase two data we already had, we're talking about 50 AML patients having been treated with the combination of anamycin and cytarabine, and the aggregate response rate suggests a complete remission rate that is more than double that of venetoclax HMA regimens in the same second-line population. And speaking of veneta clax, we know that patients who are relapsed or refractory after first-line venetoclax regimens, they're among the hardest to treat. Well, 17 of the 45 patients we reported on had received some form of veneteclax as part of their first- line therapy. And across that entire subgroup, which by the way includes patients who were in the control arm, we saw a 29% and 47% CR and CRC response rate respectively. Now, because those figures include control arm patients, they are, if anything, a conservative view of what anamycin is contributing in this population. That, again, is much higher than would be expected from any current salvage therapy.